Management

Vectura's day-to-day operations are managed by its Executive Management team:

Christopher Blackwell, BSc, PhD Chief Executive and Executive Director

Chris Blackwell was appointed Chief Executive of Vectura in February 2004. He joined the company in 2002 as Chief Operations Officer and Executive Director. Prior to Vectura he was Director of Drug Development and an Executive Director at Scotia Pharmaceuticals Ltd, which he joined in 1998. He was previously at Hoffman La-Roche specialising in project management, where he became UK Director, Global Project Management in 1996, and Glaxo Research and Development as a Clinical Pharmacologist.

Chris trained as a research scientist at the University of Bath, where in 1988 he completed his doctorate investigating free radicals and reperfusion-induced arrhythmias.

In July 2006 Chris was appointed Non-Executive Director of AGI Therapeutics plc, a speciality pharmaceutical company focused on gastrointestinal drug products.

Anne P Hyland, BBS, FCA, FITI Chief Financial Officer, Company Secretary and Executive Director

Anne Hyland was appointed Chief Financial Officer, Company Secretary and Executive Director of Vectura in March 2002. Prior to this, she was a Director of Corporate Finance at Celltech Group plc. Other positions held at Celltech included Group Financial Controller and Finance Director for the Celltech/Medeva UK Division. She joined Celltech following the merger with Medeva plc, where she was Finance Director for the UK Division. Previously, she was the Medeva Group Financial Controller where, through a period of rapid growth, she was responsible for managing treasury, tax, internal and external reporting, and acquisition and disposal activity.

Anne joined Medeva from KPMG, London, where she was an audit manager and gained exposure to corporate finance, advisory and due diligence work.

She has a Business Studies degree from Trinity College, Dublin, and is a Fellow of the Institute of Chartered Accountants, Ireland and a Fellow of the Institute of Taxation, Ireland.

Tim Wright, BSc, PhD, MBA Commercial Director

Tim Wright joined Vectura as Commercial Director in March 2005. Prior to joining Vectura he gained a breadth of experience in business development and licensing in a number of senior roles at BTG plc, latterly as Vice President Business Development and Licensing, Oncology, and as Director of Business Development at DevCo Pharmaceuticals where he was successful in building a portfolio of neuroscience development candidates.

Between 1986 and 1999, Tim held a number of management positions at GlaxoWellcome Research and Development, both in Clinical Pharmacology and Medical Operations and in project management at Simbec Research Limited.

Tim trained as a research scientist at London University, obtaining a PhD in neuroendocrinology in 1987 and an MBA from London Business School Executive Programme in 1994.

Mark J Main, BSc, PhD Development Director

Mark Main joined Vectura as Development Director in May 2004. Prior to joining Vectura, he was with Powderject Pharmaceuticals, which he joined in 2001 to lead multi-disciplinary development teams for both drug delivery and vaccine products involving all aspects of the drug/device development process.

He was previously with Sterling Winthrop in 1986 and subsequently Parke-Davis, Ipsen International, and Scotia Pharmaceuticals, gaining extensive experience of clinical development and project management in the areas of cardiovascular and oncological treatment.

Mark trained as a research scientist at St George's Hospital Medical School, where he gained his doctorate investigating the prevention of ischaemia-induced damage of the mammalian myocardium.

Stephen W Eason, BSc (Eng) Director of Device Development

Stephen Eason joined Vectura as Director of Device Development in February 2002 when the Aspirair® inhaler technology and staff were acquired from Cambridge Consultants Ltd, where he was an associate director. He had previously initiated and led the Aspirair® development programme at CCL and has subsequently initiated and led the GyroHaler® development programme for Vectura. While at CCL Stephen carried out significant product developments in the areas of inhalation, injection and infusion products.

Prior to joining CCL, Stephen worked for seven years as a design and development engineer within manufacturing industry, first with the TI Group and then with Baxter Healthcare.

Stephen studied Mechanical Engineering at the Imperial College of Science and Technology, London.

Martin J Shott, PhD, MRPharmS Pharmaceutical Operations Director

Martin Shott joined Vectura as Director Pharmaceutical Operations in October 2002, having had a wide-range of experience from within the pharmaceutical industry. Prior to joining Vectura, he worked for four years at Innovata Biomed as Associate Director of Research and Development.

Martin has gained extensive experience in the UK and Europe working as a senior manager at several companies including Lers-Synthelabo and Ciba-Geigy (later Novartis) where he managed the global DPI development unit based in the UK.

He trained as a research scientist, during which time he investigated the compression of pharmaceutical powders for a PhD at Nottingham University, while continuing to work in the industry. He is a member of the Royal Pharmaceutical Society of Great Britain.

Colin C Dalton, BTech (Hons), PhD Director of Intellectual Property and Corporate Affairs

Colin Dalton joined Vectura’s Executive Management team after its acquisition of Innovata plc in January 2007. He was previously Corporate Development Director with Innovata and Quadrant, a formulation company acquired by Innovata. For five years prior to Quadrant, he was Director of Business Development at GSK Biologicals where he managed a group responsible for licensing new products and technologies, collaborations and alliances.

He previously worked in business development at Quadrant Healthcare plc and British Sugar plc and was a senior consultant in the biotechnology practice at PA Consulting. He started his career as a fermentation scientist at BP Co Ltd. He trained as an applied biologist at Brunel University and obtained a PhD in 1977 at Leicester University.